Pharmaceutical News

RSS

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development.

9 May 2011

Merrimack acquires development and commercialization rights to MM-398 in Europe, Asia

Merrimack Pharmaceuticals, Inc. and PharmaEngine, Inc. today announced the signing of an agreement under which Merrimack has acquired the rights to develop and commercialize MM-398 in Europe and Asia.

9 May 2011

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.

9 May 2011

Best Practices' report provides marketing, branding strategies for expanding multi-drug portfolio

In today's highly competitive marketplace, bio-pharmaceutical companies often look to expand their product portfolios in the same indication. This "double-dipping" can result in a new brand gaining more profitability at the expense of a more established brand.

9 May 2011

Adalimumab remains in newborn's bloodstream for at least three months

Adalimumab, a drug often prescribed for women with Crohn's disease, actively crosses the placenta during the final trimester of pregnancy and remains in a newborn's bloodstream for at least three months, researchers at the University of California San Francisco have found.

9 May 2011

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, announces that the U.S. Food and Drug Administration has awarded Orphan Drug designation for MCD-386CR, its lead drug candidate, for the treatment of Progressive Supranuclear Palsy.

9 May 2011

Cegedim Relationship Management's co-pay savings card programs presented at PMSA conference

The OPUS Health division of Cegedim Relationship Management conducted a presentation entitled Best Practices in ROI Methodologies in Analyzing the Effectiveness of Patient Co-pay Savings Cards at the 2011 Annual Pharmaceutical Management Science Association Conference in Miami, Florida.

7 May 2011

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has published an article in its current issue entitled, "Electroporation Delivery of DNA Vaccines: Prospects for Success."

7 May 2011

Medical societies still 'welcome' drug company support

Concerns about the influence of industry money have prompted universities such as Stanford and the University of Colorado-Denver to ban drug sales representatives from the halls of their hospitals and bar doctors from paid promotional speaking.

7 May 2011

Study finds 4.5 million outpatient visits yearly due to adverse drug effects

Harmful effects of medication bring an estimated 4.5 million patients to doctors' offices and emergency rooms yearly, according to a new study, and people who take multiple medications are particularly vulnerable to unpleasant or dangerous side effects, allergic reactions and toxicity.

7 May 2011

Alza files patent infringement suit against Impax in connection with Concerta

Impax Laboratories, Inc. today confirms that Alza Corporation has filed suit for patent infringement against Impax in the United States District Court for the District of Delaware in connection with Concerta extended-release 18, 27 and 36 mg tablets.

7 May 2011

Caisse des Dépôts, sanofi-aventis sign memorandum of understanding for Caisse des Dépôts Investment in Biocitech life science technology park

sanofi-aventis and France’s Caisse des Dépôts announce today that the Caisse des Depots will acquire an interest in the Paris-based Biocitech life sciences technology park. Biocitech plays a key role in the development of the biotechnology industry in the department of Seine-Saint-Denis and the Greater Paris region.

7 May 2011

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

On Thursday, the U.S. Food and Drug Administration approved Afinitor (everolimus) to treat patients with progressive neuroendocrine tumors located in the pancreas (PNET) that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

7 May 2011

Novartis receives FDA approval for Afinitor to treat pancreatic neuroendocrine tumors

Yesterday, the U.S. Food and Drug Administration approved the Novartis drug Afinitor for the treatment of advanced pancreatic neuroendocrine tumors.

7 May 2011

Inhalation therapy might halt and reverse progression of pulmonary arterial hypertension

Patients with pulmonary arterial hypertension struggle with severe symptoms, which include shortness of breath, exhaustion and a lack of vitality. Moreover, the disease, which is more common in women, often claims the patient's life within a few years of its development.

6 May 2011

SaveRxCanada.com reveals top reasons why U.S. customers select Canadian pharmacy

SaveRxCanada.com the premier Canadian pharmacy intermediary since 2002, reveals the top reasons why U.S. customers still purchase Canada drugs from a Canada pharmacy.

6 May 2011

Springer author earns ESCMID recognition for work in clinical microbiology and infectious diseases

Dr. Rino Rappuoli has been chosen to receive the 2011 ESCMID Award for Excellence on Clinical Microbiology and Infectious Diseases by the European Society of Clinical Microbiology and Infectious Diseases.

6 May 2011

SAS Health Care & Life Sciences Executive Conference to discuss clinical research best practices

Drug developers are challenged as never before to deliver innovative medicines through a business model that boosts the bottom line. Optimizing clinical trial design and portfolio management is paramount for managing outcomes and costs, and for rapidly advancing new drugs to the marketplace.

6 May 2011

TB medication variations in private markets could harm treatment efforts, study says

A wide variation in the dosages and forms of medicines prescribed by private physicians to patients with tuberculosis in developing countries could lead to the development of more drug-resistant strains of the bacterial infection, according to a study published online Wednesday in PLoS One, the Financial Times reports.

6 May 2011

Patent expiries, generic pricing policies may be factors in slow drug spending growth

Although drugs remain an important cost driver in Canada's health system, growth in spending has slowed to its lowest rate in 14 years, according to a new report released today by the Canadian Institute for Health Information.

6 May 2011

Pharmaceutical News

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

Merrimack acquires development and commercialization rights to MM-398 in Europe, Asia

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Best Practices' report provides marketing, branding strategies for expanding multi-drug portfolio

Adalimumab remains in newborn's bloodstream for at least three months

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

Cegedim Relationship Management's co-pay savings card programs presented at PMSA conference

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Medical societies still 'welcome' drug company support

Study finds 4.5 million outpatient visits yearly due to adverse drug effects

Alza files patent infringement suit against Impax in connection with Concerta

Caisse des Dépôts, sanofi-aventis sign memorandum of understanding for Caisse des Dépôts Investment in Biocitech life science technology park

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

Novartis receives FDA approval for Afinitor to treat pancreatic neuroendocrine tumors

Inhalation therapy might halt and reverse progression of pulmonary arterial hypertension

SaveRxCanada.com reveals top reasons why U.S. customers select Canadian pharmacy

Springer author earns ESCMID recognition for work in clinical microbiology and infectious diseases

SAS Health Care & Life Sciences Executive Conference to discuss clinical research best practices

TB medication variations in private markets could harm treatment efforts, study says

Patent expiries, generic pricing policies may be factors in slow drug spending growth

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News